$43.87
-0.17(-0.39%)
Mkt Cap $11.8B
$34.13
$46.61
52-Week Range
At A Glance
1
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.
2
Revenue is primarily driven by Product Gross (36.9%) and Product (26.3%).
3
Most recently: . Results of Operations and Financial Condition. On February 10, 2026, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the (2026-02-10).
$11.8B
Market Cap
$2.3B
Revenue
$773M
Net Income
Employees1,147
Fundamentals
How The Business Makes Money
Revenue by Segment
Product Gross36.9%($7.8B)
Product26.3%($5.6B)
Cabometyx26.1%($5.5B)
License6.7%($1.4B)
Collaboration3.6%($758M)
Service0.3%($66M)
Cometriq0.2%($35M)
Revenue by Geography
US88.8%($5.6B)
Europe9.8%($618M)
JP1.5%($92M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0000939767
ISINUS30161Q1040
CUSIP30161Q104
Phone650 837 7000
Address1851 Harbor Bay Parkway, Alameda, CA, 94502, US
SEC EDGAR